Armistice Capital, LLC Paratek Pharmaceuticals, Inc. Transaction History

Armistice Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$2.67 - $4.97 $6.06 Million - $11.3 Million	-2,268,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.93 - $4.5 $2.04 Million - $3.13 Million	696,000 Added 44.27%	2,268,000 $9.14 Million
Q3 2019 Nov 14, 2019	SELL	$3.08 - $5.76 $2.79 Million - $5.22 Million	-906,000 Reduced 36.56%	1,572,000 $6.79 Million
Q2 2019 Aug 14, 2019	BUY	$3.47 - $6.32 $1.23 Million - $2.24 Million	354,000 Added 16.67%	2,478,000 $9.89 Million
Q1 2019 May 15, 2019	BUY	$5.36 - $7.24 $836,160 - $1.13 Million	156,000 Added 7.93%	2,124,000 $11.4 Million
Q4 2018 Feb 14, 2019	BUY	$4.8 - $11.6 $3.69 Million - $8.91 Million	768,000 Added 64.0%	1,968,000 $10.1 Million
Q3 2018 Nov 14, 2018	BUY	$9.05 - $10.95 $615,400 - $744,600	68,000 Added 6.01%	1,200,000 $11.6 Million
Q2 2018 Aug 14, 2018	BUY	$10.2 - $13.9 $5.63 Million - $7.67 Million	552,000 Added 95.17%	1,132,000 $11.5 Million
Q1 2018 May 15, 2018	BUY	$12.65 - $18.85 $7.34 Million - $10.9 Million	580,000 New	580,000 $7.54 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.